All In Biotech

Drug Trial Radar · NCT04902105

Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite

A Phase 1, Open-Label, Fixed Sequence, Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of Uridine 5'-Diphosphate-glucuronosyltransferases (UGTs) on the Pharmacokinetics of Ecopipam Tablets and Its Active Metabolite (EBS-101-40853) in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Jul 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

May 13, 2021

Primary completion

Jul 6, 2021

Study completion Jul 6, 2021

Sponsor

Lead sponsor
Emalex Biosciences Inc.Industry
Sponsor type
Industry
Collaborators
Syneos Health; Nuventra, Inc.
First posted
May 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single center, open-label, fixed sequence, drug-drug interaction (DDI) study in healthy subjects.

Conditions

  • Drug Interaction

Interventions

  • ecopipam HCLDrug

    oral tablets

  • Mefenamic acidDrug

    oral capsules

  • Divalproex Sodium ERDrug

    oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax of ecopipam in the presence of mefenamic acidTime frame: Up to Day 16
  2. Cmax of ecopipam in the absence of mefenamic acidTime frame: Up to Day 16
  3. Cmax of ecopipam in the presence of divalproex sodium ERTime frame: Up to Day 16
  4. Cmax of ecopipam in the absence of divalproex sodium ERTime frame: Up to Day 16
  5. AUCinf of ecopipam in the presence of mefenamic acidTime frame: Up to Day 16
  6. AUCinf of ecopipam in the absence of mefenamic acidTime frame: Up to Day 16
  7. AUCinf of ecopipam in the presence of divalproex sodium ERTime frame: Up to Day 16
  8. AUCinf of ecopipam in the absence of divalproex sodium ERTime frame: Up to Day 16
  9. AUC0-143 of ecopipam in the presence of mefenamic acidTime frame: Up to Day 16
  10. AUC0-143 of ecopipam in the absence of mefenamic acidTime frame: Up to Day 16
  11. AUC0-143 of ecopipam in the presence of divalproex sodium ERTime frame: Up to Day 16
  12. AUC0-143 of ecopipam in the absence of divalproex sodium ERTime frame: Up to Day 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Syneos Health Clinical Research Services, LLC.

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.